
RNA-guided programmable therapeutics for fibrosis, Samir Ounzain, CEO & Co-Founder, HAYA Tx
Biotech 2050 Podcast
How COVID's Discovery Platform Can Help You Get Your Asset to Clinic
Samir: There is definitely a laser focus on how are you getting your asset to clinic. What is the roadmap? What is the path? How are you going to do that efficiently, both in terms of time and resource? And I think over the last year has definitely coming to focus from an investor perspective. So for our first organ or indication of heart failure, that was driven by the biology and the science actually. But then obviously once we had this very compelling in Vivo data, we then had to think we can't go into large heart failure indications. Then it was really what are the best patient population that allows us to get clinical proof of concept rapidly and effectively.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.